New study explores cancer drug safety for patients with liver issues
NCT ID NCT05661461
First seen Nov 14, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This early-phase study tests the safety of a drug called nab-sirolimus in adults with advanced solid tumors who also have moderate liver impairment. About 28 participants will receive the drug to see how their bodies process it and what side effects occur. The goal is to find the right dose for this group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact
Contact Email: •••••@•••••
-
South Texas Accelerated Research Therapeutics, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.